Crossmark

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients

Crossref DOI link: https://doi.org/10.1186/s13613-023-01153-6

Published Print: 2023

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Barbier, François

Hraiech, Sami

Kernéis, Solen

Veluppillai, Nathanaël

Pajot, Olivier

Poissy, Julien

Roux, Damien

Zahar, Jean-Ralph
License Information

Text and Data Mining valid from 2023-01-01

Text and Data Mining valid from 2023-01-01

Version of Record valid from 2025-11-19
More Information

This article is maintained by: Elsevier

Article Title: Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients

Journal Title: Annals of Intensive Care

CrossRef DOI link to publisher maintained version: https://doi.org/10.1186/s13613-023-01153-6

Content Type: article

Copyright: Copyright © 2023 The Author(s) 2023. Published by Elsevier Masson SAS